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ABSTRACT
Introduction: Generalized anxiety disorder
(GAD) is a chronic disease with waxing and
waning of symptoms. This is the first
comprehensive economic model developed to
reflect the nature and course of GAD.
Methods: An incidence-based probabilistic
Markov model was developed reflecting nine
GAD health states (HS): clinical assessments
(three HS), maintenance therapies (four HS),
discontinuation (one HS), and death (one HS).
A probability curve of the GAD onset (ages
18–80) determined entry into the model and
assumed patients retained the diagnoses
until death. Canadian Psychiatric Association
(CPA) guidelines determined pharmacotherapy,
with revisions/validation by an expert
panel. Direct costs (clinician, pharmacotherapy,
hospitalization) were retrieved from government
publications. Remission was based on pooled-
analysis of CPA-cited evidence. Remaining
clinical rates, absenteeism, and hospitalization
were retrieved from the literature. Direct costs
were attributed throughout the model except for
the discontinuation and death HS. Indirect costs
(wage rate) were retrieved from government
publications and the literature (absenteeism),
and were attributed to patients with GAD
B65 years of age. Results were discounted at 5%
and results expressed in 2008 Canadian dollars.
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Results: The mean lifetime cost of illness (COI)
was estimated to be $31,213 (SD $9,100) per
patient. The cost of absenteeism accounted for
96% of the mean COI. The mean age of onset
was 31 years and approximately 19% did not
respond to pharmacotherapy. Over 85% of
patients discontinued treatment by the fourth
cycle (2nd year of therapy). Over the course of
the model, a mean of 53% of patients relapsed,
with an average rate of 0.79 relapses per patient.
On average and over a lifetime, the disorder
went unmanaged over a period of 14 (SD 9)
years. The model was most sensitive to
absenteeism.
Conclusion: GAD is a costly disease with a
lifetime COI \$32k/patient, with absenteeism
exerting a significant impact.
Keywords: Absenteeism; Cost of illness;
Decision model; Economics; Generalized
anxiety; Markov model; Pharmacotherapy
INTRODUCTION
The resources needed to meet the demand
for healthcare services, including mental
health, are scarce and are becoming more so.
Decision-makers increasingly rely on economic
evaluations to help make choices under budget
constraints [1]. Generalized anxiety disorder
(GAD) imposes a significant individual and
societal burden; hampering economic
productivity and contributing to healthcare
service utilization [2–4]. The estimated lifetime
prevalence of GAD ranges between 2.4 and 5.7%
in the general population [2, 3, 5–7]. The clinical
course forGADisdifficult tomap dueto the lackof
prospective epidemiologic studies [8]. However,
retrospective studies indicate that GAD is a
chronic disease with fluctuating symptoms,
characterized by excessive, uncontrolled, and
often irrational and disproportionate concern
about everyday issues [8–11]. While the
management of GAD includes both
psychological and pharmacologic treatment,
either alone or in combination, most patients
are treated with pharmacotherapy because of
limited access to cognitive behavior therapy
(CBT) [9]. Furthermore, there is insufficient
evidence for the combination to be superior to
either treatment form alone [12].
Economic evaluations of healthcare services
or products may be categorized as either ‘‘full’’
or ‘‘partial’’ depending on the scope of analysis.
Examples of full economic evaluations include
cost-benefit analysis (CBA), cost-effectiveness
analysis (CEA), cost-minimization analysis
(CMA), and cost-utility analysis (CUA).
Parameters of an economic evaluation include
costs, consequences, and the subsequent
comparison of those costs and consequences
through an incremental cost-effectiveness ratio
(ICER) between targeted comparators. Studies
limited to the economic component of a full
economic evaluation have been referred to as
partial economic evaluations. Examples of such
studies include cost-description studies (cost or
burden of illness, resource utilization), cost-
outcome description studies (single service or
program), and cost-comparison. All of these
approaches have been used previously in
psychiatry.
Despite the chronicity of the disorder,
longitudinal economic evaluations related to
GAD have been limited to time periods of
18 months or less; failing to reflect the
protracted course of the disorder and leaving
the lifetime cost of the disorder to be
determined [4]. The CEA related to GAD were
designed using summary population data or
conventional decision-tree models and were
often less than a year in duration [4].
Furthermore, previous cost of illness (COI)
studies of GAD focused solely on its direct
Page 2 of 17 Neurol Ther (2012) 1:1
123
economic impact on healthcare systems, and
did not take into consideration the disorder’s
impact on productivity [4]. The purpose of this
study was to develop a dynamic decision model,
reflecting the nature of the disorder, and to
quantify its lifetime COI per patient from a
societal perspective in Canada.
Decision analysis is a mathematical model
that incorporates a systematic and quantitative
approach to decision-making under conditions
of uncertainty. The framework for decision
analysis is based on research by von Neumann
and Morgenstern [13], known as the theory of
expected utility. The premise of this theory is
that rational decision makers would choose an
option that maximizes their expected utility.
However, given the abundance or complexity of
information, the ability of decision-makers to
process and arrive at a rational decision may be
subject to bias. The structured approach
afforded by decision analysis models enables
the decision to be based on a more extensive
range of data and a formal synthesis of the
information [14], thereby, supplementing
reasoning abilities and reducing bias.
METHODS
Subjects
The target population was adults (aged
18–80 years) with a primary diagnosis of GAD
fulfilling the Diagnostic and Statistical Manual
IV (DSM-IV) or International Classification of
Disease-10 (ICD-10) criteria. The choice of the
lower age limit corresponded to the age at
which patients were usually recruited into the
Canadian Psychiatric Association (CPA)-cited
evidence [12]. Canadian life expectancy
published by Statistics Canada set the upper
age boundary [15].
Although several studies compare suicidal
ideation in a GAD cohort to a co-morbid GAD
cohort and other anxiety disorder, none report
raw data of suicide rates attributable to GAD.
The age-specific attrition rate infers that these
rates include suicide rates from a population
that includes all mental disorders. Therefore,
the net increase of suicide as a direct result of
GAD is hypothesized to be negligible for the
purposes of this study.
Pharmacoeconomic Model
A decision analytic framework was used to
model the relationship between GAD, the
management of the disorder, and the cost
consequences of these assumptions. TreeAge
Pro Suite 2009 (TreeAge Software Inc.,
Williamstown, MA, USA) software was used to
develop an incidence-based, probabilistic
Markov model.
The analysis was undertaken to evaluate
both direct and indirect costs to society. The
former included family practice and specialist
physician fees, drugs and drug dispensing fees,
as well as the cost of hospital stay. The latter was
estimated by measuring foregone wages due to
absenteeism, which was also used as a proxy for
valuation of leisure time or time lost for
those not currently employed. The cost of
absenteeism was not attributed to patients
over the age of 65 years. Costs related to
co-morbid psychiatric disorders, such as
depression, or somatic conditions, such as
irritable bowel syndrome (IBS), were not
included in the analysis.
Health States
The model included nine health states (Table 1).
Creation of these health states was guided
by tolerance of medication and optimal
pharmacotherapeutic management of GAD.
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Health states also modeled patients who
discontinued treatment or sought treatment
anew. Patients entered the model once
diagnosed with GAD by a physician in family
practice. Upon suboptimal response (to first-
line treatment), patients were assessed by a
psychiatrist to determine appropriate
therapeutic options. Four other health states
modeled patients on their respective
maintenance therapy. ‘‘Death’’ was the
absorbing state. A ‘‘bubble’’ diagram depicting
the health states and transitions among the
health states is presented in Fig. 1. The length of
time that patients’ remained in the model was
based on their life expectancy from the onset of
illness. The distribution of patients’ ages at disease
onset was based on peer-reviewed literature [16].
Patient Pathways and Cycle Length
Within each health state, a probability matrix was
embedded to describe pathways patients may
have taken while in that health state. The matrix
within each health state, with the exception of
‘‘death,’’ began with the application ofanattrition
rate that was equivalent to the probability of
death from all causes, allowing for patients to exit
the model. Additional pathways included change
of therapy, dose titration, treatment response or
discontinuation, and disease remission or relapse.
The attrition rate was derived from Statistics
Canada age-adjusted life tables for 2000–2002
[17, 18]. The cycle length of 6 months was based
on the treatment algorithm recommended by the
CPA as well as expert opinion [12]. An example of
a decision tree is illustrated in Fig. 2.
Table 1 List and description of Markov health states
Health state number Health state descriptor Patient description
1 (initial) Family physician assessment
(initial health state)
Family practice physician initially diagnoses and treats
GAD with 1st line agents
May re-enter model after at least one cycle in treatment
discontinuation state
2 Specialist assessment 2nd line Treatment managed by a psychiatrist prescribing 2nd
line treatment options (i.e., patient Intolerant to 1st
line agents, or responded to 1st line medication but not
remitted, or neither responded nor remitted to 1st line
therapy)
3 Specialist assessment 3rd line Treatment managed by a psychiatrist prescribing 3rd line
or treatment-resistant options (i.e., intolerant or did
not respond to 1st or 2nd line pharmacotherapy)
4–7 Maintenance therapies Patients on maintenance therapy who have achieved
remission in 1st line or 2nd line health states
Patients who have achieved remission or response and
are maintained with 3rd line therapy
8 Treatment discontinued Patients discontinue therapy for any reason
9 Absorbing state Death—patients removed from model
GAD generalized anxiety disorder
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Management of GAD
Pharmacotherapeutic choices for the
management of GAD were based on CPA
guidelines [12] as well as expert opinion. The
reference case scenario considered
pharmacotherapeutic management of GAD.
First-line therapy was either a selective
serotonin re-uptake inhibitor (SSRI) or
serotonin-norepinephrine re-uptake inhibitor
(SNRI). Second-line therapy was either a first-
line agent augmented with a benzodiazepine or
a benzodiazepine as monotherapy. Adjunctive
olanzapine or risperidone, mirtazapine,
trazodone, and citalopram were recommended
as third-line options or for treatment-resistance
individuals [12]. Dosing information was taken
from the product monographs, peer-review
literature, or CPA-cited evidence [12, 19–30].
Several second and third-line agents
recommended by the guidelines were not
included in this study due to uncommon use in
clinicalpractice, oftendue tomodest efficacy, lack
of approved coverage, or both (e.g., pregabalin,
bupropion, hydroxyzine). Buspirone has limited
use due to reduced efficacy in patients who have
previously been treated with benzodiazepines
[12]. Imipramine is not used routinely due to
increased toxicity risks [12].
The CPA guidelines do not provide a
recommendation for the combination of CBT
and pharmacotherapeutic agents, citing a lack
of evidence [23–25]. However, an estimated
23% of patients with current anxiety are
treated with a combination of medication and
counseling [31]. The combination of CBT with
pharmacotherapy was considered in a
sensitivity (scenario) analysis.
Clinical Variables
The clinical rates used in this model are listed in
Table 2 [27, 32–37]. The probability of patients’
inability to tolerate pharmacotherapy was based
on peer-reviewed published literature [32, 38].
Fig. 1 Bubble diagram showing the health states and transition pathways for the Markov Model
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Fig. 2 Decision tree within the Family Physician Assessment Health State (a), decision tree (continued from a) within the
Family Physician Assessment Health State (b)
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Meta-analytic rates of adverse drug reactions
reported in major depression were used as a
proxy for GAD patients’ inability to tolerate
SSRI or SNRI agents. For benzodiazepines, data
from CPA evidence were pooled using the drop-
out rate itself as an effect size and the binomial
theorem to determine its variance; a technique
described by Einarson [39]. The rates of
patients’ inability to tolerate medication were
not required for patients treated with third-
line agents, as these rates were very infrequent.
Remission and response rates were obtained
from a previously published meta-analysis of
CPA evidence [33]. Treatment discontinuation
rates were based on peer-reviewed literature
for each treatment line where possible
[34, 35].
Relapse rates for this model were
extrapolated for the assessed patients at 6 and
12 months intervals from data reported from
the Harvard/Brown Anxiety Research Project
(HARP), an observational, longitudinal study of
patients with GAD [35]. A spontaneous
remission rate of 22.5% was assigned to a
Table 2 Clinical variables and their value inputs
Clinical parameters Probabilities
Mean Low value High value Distribution Source
1st line treatment
Inability to tolerate 0.0900 0.0470 0.1470 Triangular Machado [32]
Remission 0.3970 0.3520 0.4410 Triangular Bereza [33]
Response 0.6772 0.6409 0.7136 Triangular Bereza [33]
Discontinued treatment 0.7138 0.7022 0.7266 Triangular Mullins [34]
Benzodiazepine treatment
Inability to tolerate 0.0730 0.0450 0.1010 Triangular Pooled results
Remission 0.5350 0.4400 0.6300 Triangular Bereza [33]
Response 0.5680 0.4640 0.6720 Triangular Bereza [33]
Discontinued treatment 0.5260 0.3630 0.6613 Triangular Ohayon [35]
1st line ? benzodiazepine treatment
Inability to tolerate 0.0900 0.0470 0.1470 Triangular Machado [32]
Remission 0.4100 0.3630 0.4560 Triangular Bereza [33]
Response 0.6430 0.6020 0.6840 Triangular Bereza [33]
Discontinued treatment 0.5260 0.3630 0.6613 Triangular Vasile [27]
3rd line treatment
Remission 0.3570 0.2310 0.4820 Triangular Bereza [33]
Response 0.5490 0.3970 0.7020 Triangular Bereza [33]
Discontinued treatment 0.5260 0.3630 0.6613 Triangular Vasile [27]
Relapse 0.0250 0.0200 0.0500 Triangular Yonkers [36]
Spontaneous remission 0.2000 0.2250 0.2500 Triangular Ballenger [37]
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cohort of patients who had discontinued
treatment [37]. The rate was based on a
consensus statement from the International
Consensus Group on Depression and Anxiety.
No evidence was given for this rate nor was
spontaneous remission defined in their
statement [37]. This rate was attributed to the
‘‘Treatment Discontinued’’ health state only.
This model assumed that patients who did not
‘‘spontaneously remit’’ were experiencing GAD-
related symptoms and may or may not decide to
seek treatment.
Resource Use and Costs
Physician Costs
Economic input variables and their values for
this study are presented in Table 3 [40–47]. Fees
for family practice and psychiatry consultations
were taken from the Government of Ontario’s
Ministry of Health and Long Term Care
(MOHLTC) Schedule of Benefits for Physician
Services [41]. Patients were subject to an initial
physician assessment as well as follow-up visits
to assess tolerance, response, or remission.
Maintenance health states were attributed one
follow-up visit per cycle. No physician costs
were attributed to the ‘‘Treatment
Discontinued’’ or ‘‘Death’’ states. For subgroup
analysis, an additional ten sessions of CBT with
a psychiatrist were attributed to patients in the
‘‘Family Physician’’ and ‘‘Specialist Assessment’’
second or third-line treatment health states.
Drug Costs
Costs for pharmacotherapy were based on the
Government of Ontario, MOHLTC, Ontario
Drug Benefit (ODB): formulary/Comparative
Drug Index [44]. Costs for initial,
maintenance, and optimized daily doses were
considered separately. The dispensing fee was
taken from the Government of Ontario,
MOHLTC, ODB: dispensing fee website [40].
Prescribed drugs were assumed to have been
filled by a pharmacist in Ontario and handed to
the patient. A dispensing fee was charged for
the initial prescription, or when medication was
titrated or switched. One prescription fee of
$7 Canadian dollars (CAD) was incurred for each
6-month cycle in a ‘‘Maintenance’’ health state.
Hospitalization Costs
The 2002 Health Canada report on mental
illness in Canada reported that patients with
anxiety disorders incurred on average ten
hospitalization days in 1999 as a result of their
disorder. This rate of utilization changed little
between 1987 and 1999, ranging from 9.6 to
11.1 days [42]. Cost of hospitalization per day
was an estimation of total acute care inpatient
costs for 2004 from the Canadian Institute for
Health Information (CIHI) database available
on their web site [43]. Total hospitalization
costs attributed to GAD were calculated by
multiplying the number of hospitalization
days by the total acute care inpatient cost.
Inpatient costs were inflated to 2008 CAD using
the Consumer Price Index [48].
Indirect Costs
Indirect costs were based on number of days
absent, productivity lost from work in a given
month, and the industrial wage rate [45]. The
mean number of impaired days was derived from
Kessler’s study of two large surveys conducted in
the US: the National Co-morbidity Survey and the
Midlife Development in the US Survey. Kessler’s
study distinguished between productivity loss
while at work and work days lost [45]. The
weighted average from these surveys was
approximately 2 days/month [45]. This rate was
multiplied by the average industrial hourly wage
rate for 2008, of $21.08, to calculate indirect costs,
assuming an 8-h work day [45].
Page 8 of 17 Neurol Ther (2012) 1:1
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Table 3 Economic input and associated costs (in 2008 Canadian dollars)
Variable Distribution Low High Value Source
Direct costs
Clinician/hospital charges
Pharmacist dispensing fee Uniform $6.00 $15.00 $10.50 MOHLTC: dispensing fees [40]
Initial assessment family
practice
Uniform $42.53 $78.98 $60.75 MOHLTC: schedule of beneﬁts [41]
Follow-up family practice Uniform $21.25 $39.46 $30.35 MOHLTC: schedule of beneﬁts [41]
Initial assessment psychiatry Uniform $113.74 $211.22 $162.48 MOHLTC: schedule of beneﬁts [41]
Follow-up psychiatry Uniform $57.72 $107.19 $82.45 MOHLTC: schedule of beneﬁts [41]
Hospitalization cost
(10-day period)
Uniform $3,416.00 $6,340.00 $4,878.00 Health Canada [42]; CIHI [43]
Pharmacotherapy (mean daily cost)
Initial 1st line Uniform $0.70 $1.30 $1.00 MOHLTC:ODB: formulary [44]
Initial benzodiazepine
adjunctive 1st line
Uniform $0.80 $1.49 $1.15 MOHLTC:ODB: formulary [44]
Initial benzodiazepine
monotherapy
Uniform $0.10 $0.19 $0.15 MOHLTC:ODB: formulary [44]
Initial 3rd line Uniform $0.83 $1.55 $1.19 MOHLTC:ODB: formulary [44]








Uniform $0.16 $0.30 $0.23 MOHLTC:ODB: formulary [44]
Maintenance 3rd line Uniform $2.04 $3.79 $2.91 MOHLTC:ODB: formulary [44]
Titrated 1st line Uniform $1.19 $2.20 $1.70 MOHLTC:ODB: formulary [44]
Titrated benzodiazepine
adjunctive 1st line
Uniform $1.41 $2.63 $2.02 MOHLTC:ODB: formulary [44]
Titrated benzodiazepine
monotherapy
Uniform $0.16 $0.29 $0.22 MOHLTC:ODB: formulary [44]




Uniform $1,465.12 $2,719.60 $2,092.72 Kessler [45]; Statistics Canada [46]
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Costs related to absenteeism were attributed
to the assessment health states (i.e., ‘‘Family
Physician’’, the two ‘‘Specialist Assessment
Second-Line’’ and ‘‘Specialist Assessment Third-
Line’’), as well as to patients in the ‘‘Treatment
Discontinued’’ health state who have GAD-
related symptoms but are not seeking
treatment for the disorder (i.e., 1 minus the
spontaneous remission rate). Patients in the
four ‘‘Maintenance’’ health states were not
attributed an indirect cost as the model assumed
that while patients were in that health state, they
were able to function effectively at work.
However, it was assumed that patients not
achieving ‘‘spontaneous remission’’ would be
subject to impairment. Since indirect costs were
measured as foregone wages, indirect costs were
considered only for patients B65 years of age.
Discounting
In accordance with the Canadian guidelines for
economic evaluations of health technologies,
costs were discounted at a rate of 5% each year
and altered to 0% in the sensitivity analysis
[49].
Variability and Uncertainty
Computational validation of the model was
performed through a ‘‘debugging’’ process [50].
A one-way sensitivity analysis was also performed
to assess the impact of the parameter on the base
case result. Breakdown analysis was performed to
assess the impact of each variable on the base case
result. The model structure was confirmed by an
expert committee in the fields of mental health
and health economics.
RESULTS
The mean value of the lifetime COI per patient
with GAD was estimated to be (2008 CAD)
$31,213 (SD $9,100). The distribution of COI
values is illustrated in Fig. 3. The figure
illustrates that nearly all of the cohort exited
the model. The distribution of COI values is
(visually) negatively skewed. However, using
the formula for Pearson’s index of skewness
yields a value greater than -1.0, suggesting that
the data set is not significantly skewed, and that
the mean and standard deviation are valid
measures of central tendency and variability
(3 9 [mean - median]/standard deviation = 3 9
[$31,213 - $33,855]/$9,100 = -0.87) [51].
The cost of absenteeism accounted for 96%
of the mean COI. Pharmacotherapy contributed
1.8% to the lifetime COI, while physician fees
contributed 1.5%. Hospital costs and dispensing
fees contributed a total of 0.5% to the expected
COI.
Table 3 continued
Variable Distribution Low High Value Source
Resource use
Treatment seeking rate Triangular 0.1000 0.3300 0.2600 Wang [47]
Hospitalization rate Triangular 0.0000 0.1200 0.0600 CIHI [43]
Discount rate Uniform 0.0000 0.0500 0.0500
CIHI Canadian Institutes of Health Information,MOHLTCMinistry of Health and Long Term Care, ODB Ontario Drug
Beneﬁt
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Fig. 3 Distribution of COI values from Monte Carlo simulation. COI cost of illness
Fig. 4 Health-state cumulative transition probabilities graph. Benzo benzodiazepine
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Health state probabilities are presented in
Fig. 4. The mean age at which patients entered
the model was 31 years. Eighty-nine percent of
the patients who entered the model died from
all causes, thereby exiting the model.
Approximately 11% of the cohort remained in
the model at some point during their expectant
lifespan upon completion of the simulation.
Just over 85% of patients stopped treatment by
the fourth cycle (year 2). Over the course of the
model, a mean of 53% of patients relapsed, with
an average rate of 0.79 relapses per patient.
Approximately 19% of patients did not respond
to any pharmacotherapeutic agent. The mean
length of time during which patients were not
managed for GAD was 14 (SD 9) years. The
mean rates of epidemiologic parameters are
presented in Table 4.
Sensitivity Analysis
The COI was most sensitive to the cost of
absenteeism. The range of uncertainty for the
cost of absenteeism was $1,465–$2,720 and it
exerted the highest impact compared to all
other variables, varying the COI between
$20,500 and $37,500. The mean COI result
was robust against reasonable variations in all
other cost variables, with mean COI values
maintained at approximately $31,000. The
range of uncertainty for clinical variables was
narrower overall ($30,000–$32,000) compared
to economic variables ($20,500–$37,500).
Spontaneous remission exerted the most
uncertainty, varying the mean COI by
approximately $2,000, with the remaining
variables varying the mean COI by $200 or less.
Subanalysis
The addition of ten sessions of CBT therapy to
existing pharmacotherapy resulted in minimal
impact on the COI. Adding ten sessions of CBT
to the first-line assessment health state added
0.7% to the lifetime COI. If CBT were to be
added during the second or third-line
assessment health state, the additional cost
increased by 0.3% and 0.01%, respectively.















Mean 0.01 0.79 0.53 0.98 0.19 14.41
SD 0.10 0.92 0.50 0.13 0.39 8.74
Minimum 0.00 0.00 0.00 0.00 0.00 0.00
2.5% CL 0.00 0.00 0.00 1.00 0.00 1.00
10.0% CL 0.00 0.00 0.00 1.00 0.00 3.00
Median 0.00 1.00 1.00 1.00 0.00 14.00
90.0% CL 0.00 2.00 1.00 1.00 1.00 27.00
97.5% CL 0.00 3.00 1.00 1.00 1.00 30.50
Maximum 1.00 7.00 1.00 1.00 1.00 31.50
CL conﬁdence limit
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DISCUSSION
Arguably, the mean COI result in the present
study is a conservative estimate. This study used
2 days of lost productivity or absenteeism to
derive the COI. Recent studies have shown lost
productivity or absenteeism at 3 days or more
[52, 53]. Use of a higher ‘‘days of lost
productivity’’ would in turn produce a higher
point estimate for the authors’ mean COI.
Furthermore, costs related to absenteeism or
loss of leisure time, were not attributed to
patients over the age of 65 years. This too
would have a conservative impact on the
authors’ COI point estimate.
The COI was not sensitive to physician or
pharmacist fees or drug costs. The distributions
for physician and pharmacist fees incorporated
a wider range of uncertainty (±30% of the
likeliest value) than those published in the
Ontario Schedule of Benefits. However,
pharmacist fees may be higher than the upper
range of uncertainty in some Canadian
provinces. Furthermore, the estimated daily
cost for agents excluded from this study is
largely within the range of costs for second-line
therapy used in this model, and it is unlikely
that consideration of these agents would have a
significant impact on the mean COI.
There are no previous publications of models
reflecting the lifetime course of GAD and its
cost to society. Previous economic evaluations
of GAD were either cross-sectional or
prevalence-based in design and estimated the
healthcare costs over the short-term only. As
such, comparison of study outcomes should be
undertaken with caution. One economic
evaluation limited the assessment of cost to
medical expenses, estimating that GAD
incurred a marginal mean cost of US$2,138
(95% CI $1,641, $2,632) compared to patients
with no GAD [51]. These data were collected
and derived over a 1-year period in a cohort
taken from a healthcare charges database [54].
In contrast, depression incurred a marginal
mean cost of US$1,944 and panic disorder
incurred a marginal mean of US$1,603,
compared to patients that did not suffer from
either condition [54]. The only anxiety disorder
in the study of Marciniak et al. [54] to have
incurred a higher marginal mean cost was post-
traumatic stress disorder. Another study found
similar results, showing a significantly higher
median medical care charges in patients with
GAD than those with no GAD ($2,375 vs.
$1,448) [55]. Moreover, there is general
agreement that all anxiety disorders are under-
diagnosed and undertreated [31, 47, 56–60];
thus, limiting the usefulness of either
population based studies or COI studies using
healthcare charges alone. Furthermore, neither
productivity nor absenteeism was incorporated
into the estimation of the cost of GAD in either
of the above-mentioned COI studies.
The use of a Markov decision analytic
framework in this study allows for the
consideration of chronicity as well as for the
waxing and waning of symptoms. Furthermore,
the model could easily be adapted to estimate
cost-effectiveness by adding a second branch
comparing a novel therapeutic (e.g.,
duloxetine) to existing treatment options.
While prior to this study, there was no Markov
model for an economic evaluation of a patient
with GAD, a Markov cost utility analysis for the
treatment of major depressive disorder has been
published. In that study, the mean annual total
medical cost for escitalopram was US$907 and
US$1,633 for duloxetine [61].
No previous studies have reported treatment
patterns prescribed for GAD patients or what
access they have to therapists in a Canadian
setting. Therefore, a comparison of the
estimated mean COI to one that would reflect
Neurol Ther (2012) 1:1 Page 13 of 17
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‘‘real-life’’ management of GAD is not possible.
The subanalysis determined that combination
therapy would not have a substantial economic
impact to the COI.
Relapse rates for this study were derived from
a study by Yonkers et al. [36] who reported
cumulative relapse rates over an 8-year follow-
up period. The relapse rate used in this study
was elected assuming that a weighted mean
relapse rate could be extrapolated on to a longer
time horizon. In a sensitivity analysis, the COI
was not sensitive to the relapse rate and,
therefore, does not introduce a substantial bias
either way.
Limitations
Lack of available sources reporting both clinical
and resource utilization data was a significant
limitation to this study. Of note, remission rates
for benzodiazepines were scarce primarily due
to the quality of reporting. Discontinuation
rates for benzodiazepines were derived from a
persistence rate and none were available for
third-line treatment. Furthermore, there are no
available data regarding the Canadian
utilization patterns of drugs by GAD patients.
GAD patients often present with somatic
symptoms, such as pain, cardiac, and
gastrointestinal symptoms, but more so during
initial contact, with resulting investigations for
mental illness [47, 54–56]. A reasonable
assumption, therefore, is that prior to a
primary diagnosis of GAD, patients are referred
to one or more specialists for further assessment
of their somatic symptoms. While this
assumption is supported by several studies [47,
56–60], costs leading up to a clinical assessment
of GAD were not considered in this study, and
the authors speculate that this issue also
contributes to a conservative estimate of the
COI. Nevertheless, further study that focuses on
costs leading up to a clinical diagnosis of GAD
would significantly contribute to the existing
literature.
There were no Canadian data on utilization
patterns of drugs included in the treatment
lines. Therefore, a comparison of mean daily
costs for medication could not be validated.
However, in this study, COI was not sensitive to
drug costs. Therefore, it is likely that this lack of
data did not contribute to the uncertainty of the
estimate.
One other limitation of the present research
is that it encompasses treatment for GAD only,
excluding any treatment for any other form of
comorbid condition, such as depression, which
is highly prevalent in GAD. Even though
treatment modalities in associated mental
diseases may overlap, the authors’ COI
estimates are restricted to the studied
population and extrapolations to comorbid
GAD require cautious interpretation.
CONCLUSION
In conclusion, based on this COI, the estimated
burden of illness of GAD in Canada ranges
between $397,488,000 and $944,034,000. This
estimated range is based on a lifetime
prevalence rate of 2.4–5.7% and 26 million
people over the age of 15 years in Canada in
2006. As previously discussed, the authors
believe this to be a conservative estimate.
Comparison of the burden of illness between
studies should be undertaken with extreme
caution, given the variability of methods and
variables included in the analysis. However, the
economic burden of illness for 1998, published
by Health Canada, reports total costs (direct and
indirect) for mental disorders at $7.9 billion
dollars. Discounting the 2008 burden of illness
at 5% per annum, yields a discounted estimate
between $244,022,000 and $579,553,070.
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Again, with caution, one may infer that GAD
contributes between 3.1% and 7.3% to the
burden of mental health in Canada.
Given the above limitations, this model
reflects the long-term course of GAD, providing
a reasonableestimateof its societal impact. From a
societal perspective, absenteeism exerts a
significant impact to the cost of illness of GAD.
A lack of prospective clinical data contributes to
the uncertainty of the COI estimate.
Future investigations of this model using
prospective data would be valuable. Research
determining which therapies are most
efficacious given patient and disease
characteristics, such as severity of GAD, age of
patient, or for treatment resistant patients, may
improve the estimate of the COI of GAD.
Furthermore, research into the societal cost of
GAD prior to the primary diagnosis would also
provide insight into a more precise estimate of
the cost of GAD from a societal perspective.
Resource utilization of Canadian treatment
patterns for GAD would also be useful to
estimate COI and to assess whether guidelines
are followed.
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